Table 1.
Systemic exposure and bioavailability of fluticasone propionate administered as an aqueous nasal spray or nasal drop formulation in 12 healthy volunteers
| FP formulation | AUC (pg ml−1 h) | Cmax (pg ml−1) | tmax (h) |
|---|---|---|---|
| Nasal spray | 67.5 ± 20.7 | 31.4 ± 5.0 | 0.9 ± 0.4 |
| (800 µg tds) | (0–248.0) | (0–52.9) | (0.2–4.0) |
| Nasal drops | 8.5 ± 4.4 | 14.5 ± 3.8 | 0.36 ± 0.1 |
| (800 µg tds) | (0–36.6) | (0–33.2) | (0.08–0.75) |
| Median difference | 48.4 | 24.4 | 0.33 |
| 95% CI | (17.2, 107.8) | (1.5, 31.3) | (0.13, 1.76) |
| P | 0.005 | 0.026 | 0.25 |
Results are expressed as the mean±standard error (range). FP: fluticasone propionate, tds: three times daily.